Georgia Southern University

Digital Commons@Georgia Southern
7th Annual Rural HIV Research and Training
Conference
Sep 22nd, 9:00 AM - 10:00 AM

Federal Policy Update
Carl Schmid

Follow this and additional works at: https://digitalcommons.georgiasouthern.edu/ruralhiv
Recommended Citation
Schmid, Carl, "Federal Policy Update" (2018). 7th Annual Rural HIV Research and Training Conference. 10.
https://digitalcommons.georgiasouthern.edu/ruralhiv/2018/2018/10

This presentation (open access) is brought to you for free and open access by the Conferences & Events at Digital Commons@Georgia Southern. It has
been accepted for inclusion in 7th Annual Rural HIV Research and Training Conference by an authorized administrator of Digital Commons@Georgia
Southern. For more information, please contact digitalcommons@georgiasouthern.edu.

Federal Policy Update
Carl Schmid
Deputy Executive Director
The AIDS Institute

6th Annual Rural HIV Research and Training Conference | September 21-22, 2018 | Savannah, GA

Disclosure Information

I do not have any conflicts of interest to disclose
and I do not intend to discuss off label use of any
drug or treatment during this discussion.

• Learn how Congress and the Administration are:
• addressing the opioid epidemic and the associated increases
in HIV due to injection drug use
• funding HIV programs as part of the annual budget and
appropriations process

• Learn what is happening to implementation of the ACA &
other access to care and treatment issues
• Learn how current Ryan White Program funding is distributed
to states and efforts to improve equity

HIV and the
Opioid
Epidemic
Response by Congress and
the Administration

Polling Question

CDC. HIV Diagnoses Among People Who Inject Drugs — United States, 2010–2016. http://www.natap.org/2018/CROI/1430_Lyss_970.pdf

• 350% increase in new HCV
cases from 2010-2016
• 22% increase in 2016
• 70+% of new cases due to
injection drug use
• Large number of the new
cases among young adults
• HCV remains the leading
infectious disease killer in
the U.S.

•

Reversal of long-time
reduction in new HBV
cases

•

20% increase in 2015

•

First increase in 10 years

•

Spike in new cases in the
Appalachian region

•

Introduced in March 2018 by Reps. Leonard Lance (RNJ) and Joseph Kennedy III (D-MA)

•

Senate version introduced by Sens. Todd Young (RIN), Tammy Baldwin (D-WI), and Edward Markey (DMA)

•

Authorizes $40 million a year over five years to the
CDC

•

Enables state and local governments and others to
respond to the growing number of opioid-related
cases of infectious diseases, such as HIV and hepatitis

•

Grantees can use the resources for surveillance,
testing, prevention, and linkage to care and
treatment for infectious diseases

• Included in the “SUPPORT for Patients and Communities Act” (H.R.6),
the House the opioid package
– Passed the House in June 2018

• Included in the “Opioid Crisis Response Act of 2018” (S.2680), the
Senate opioid package
– Passed the Senate in September 2018

• House and Senate now must reconcile differences between the bills

Total U.S. Drug Deaths

•
•

•
•

•

Reauthorizes the State Targeted Response
grant program
Authorizes new grant program at SAMHSA
for creation of Comprehensive Opioid
Recovery Centers
Encourages development of best practices
for recovery housing
Authorizes grant program to implement
policies and procedures to individuals who
have experienced an opioid overdose
Expands access to Medication-Assisted
Treatment

•
•
•

$6 billion in new opioid funding agreed to in February as part of budget deal
Plus $500 million already approved in the 21st Century Cures Act
FY18 Omnibus Appropriations bill included more than $3 billion
– SAMHSA ($1.4 billion)
• New State Opioid Response Grant program ($1 billion)
• Mental Health Block Grant ($160 million increase)

– NIH - opioid addiction research ($500 million)
– CDC - opioid overdose prevention, surveillance, and improving state prescription
drug monitoring programs ($350 million)
– HRSA - improving access to addiction treatment in rural and other underserved
areas, including funding Rural Communities Opioid Response grants ($415 million)

Grantees will receive up to $200,000 for one year
Used to develop plans to implement opioid use disorder prevention,
treatment, and recovery interventions designed to reduce opioid overdoses
among rural populations
• Award 75 grants
• Initiative is part of a multi-year
Rural Communities Opioid Response
• Ryan White HIV/AIDS clinics and
HIV and HCV prevention organizations
able to apply
•
•

Funding for
Domestic HIV
Programs

Polling Question

•

Proposed cuts
–
–
–
–
–

•

CDC HIV Prevention: -$148 m
CDC STD Prevention: -$22 m
NIH AIDS Research: -$550 m
SAMHSA Minority AIDS Programs: -$17 m
HOPWA: -$26 m

Proposed Program Eliminations
–
–
–
–

Ryan White AETCs: -$34 m
Ryan White SPNS: -$25 m
Teen Pregnancy Prevention Program: -$101 m
HHS Secretary’s Minority AIDS Initiative Fund: -$54 m

• House
– Proposed cuts
• SAMHSA Minority AIDS Programs: -$17 m

– Proposed Program Eliminations
• Teen Pregnancy Prevention Program: $101 m
• Title X Family Planning: -$286 m
• SMAIF: -$116 m

– “Sexual Risk Avoidance” AbstinenceOnly: +$5 m

• Senate
– Proposed cuts
• HOPWA: -$26 m

– “Sexual Risk Avoidance”
Abstinence-Only: +$10 m

• All proposed cuts and eliminations were not agreed to
• Most domestic HIV/AIDS programs level funded
• Increases
–
–
–
–

CDC STD Prevention: +$5 m
CDC Division of Viral Hepatitis: +$5 m
HOPWA: +$19 m
NIH Total: +$3 b

– $10 m increase to “Sexual Risk Avoidance” Abstinence-Only Programs

•

Proposed cuts
–
–
–
–
–

•

CDC HIV Prevention: -$40 m
CDC STD Prevention: -$5 m
CDC Viral Hepatitis Prevention: -$5 m
NIH AIDS Research: -$89 m
HOPWA: -$45 m

Proposed Program Eliminations
–
–
–
–
–

Ryan White AETCs: -$34 m
Ryan White SPNS: -$25 m
SMAIF: -$54 m
SAMHSA MAI: -$116 m
Teen Pregnancy Prevention: -$101 m

• House
– Proposed Program Eliminations
• Teen Pregnancy Prevention Program: -$101 m
• Title X: -$287 m

– “Sexual Risk Avoidance” Abstinence-Only: +$5 m

• Senate
– “Sexual Risk Avoidance” Abstinence-Only: +$10 m

• New CDC Initiative
– President: +$40 m
– House: +$20 m
– Senate: +$5 m

• SAMHSA Reducing IDU/HIV,
Hepatitis
– President: +$150 m

• HOPWA
– House: +$18 m

• House & Senate Passing Spending
Bills
• Combining Bills into “Minibuses”
• Fiscal Year Ends October 30th
• Labor HHS expected to pass in
time
• Some federal agencies will be on a
Continuing Resolution until after
mid-term election
• Labor HHS proposed cuts rejected

Affordable Care
Act and Access to
Care and
Treatment

Polling Question

•
•
•
•
•
•
•
•
•

Navigator funding cuts
Shortened enrollment periods
Elimination of Cost-Sharing Reduction (CSR) payments
Individual mandate penalty repealed
Essential Health Benefit (EHB) benchmark changes
Association health plans (AHPs)
Short-term limited duration plans
Medicaid 1115 waivers
Pre-existing condition protections

Instituted by insurers and pharmacy benefit managers (PBMs) that
prevent manufacturer copay assistance contributions from counting
towards a beneficiary’s deductible and maximum out-of-pocket
spending limits.
• Many consumers with chronic and complex conditions rely on
manufacturer co-pay cards to defray the cost of their
medications
• For HIV treatment, there are very few generic alternatives
available to brand-name drugs and for PrEP and the new class of
curative HCV treatment
• Co-pay accumulator policies – when applied to patients with no
alternative – disrupt access to treatment

Plan
Ambetter

Based on personal communication, currently allows the use of copayment assistance
cards and they can be applied to the member’s deductible.

Florida Blue

We reserve the right not to apply manufacturer or provider cost share assistance
program payments (e.g., manufacturer cost share assistance, manufacturer discount
plans, and/or manufacturer coupons) to the Deductible or Out-of-Pocket maximums.
Based on personal communication, currently not applying the copay accumulator
program

Health
First

Molina

BlueSelect Silver 1443
Schedule of Benefits
Page 47

Based on personal communication, currently do not permit copay cards to count towards
the members deductible.
Please note, Cost Sharing reduction for any prescription drugs obtained by You through
the use of a discount card or coupon provided by a prescription drug manufacturer will
not apply toward any Deductible or the Annual Out-of-Pocket Maximum under Your Plan.

2018 Molina Healthcare
of Florida, Inc.
Agreement and
Individual Evidence of
Coverage Page 72

• Plan annual OOP maximum: $6,000
• Deductible (combined medical and Rx): $3,000
• Drug cost sharing for preferred brand: $50 after
deductible
• Manufacturer co-pay assistance program
annual maximum: $6,000
• WAC monthly drug price: $3,090
3
2

Medication Costs without Co-pay Accumulator
Consumer
January

$0

Manufacturer Co-pay
Card
$3,050 Plan deductible met

February

$0

$50

March

$0

$50

April - December

$0

$450 ($50/month)

Total

$0

$3,600

Total collected by Insurance
Plan

$3,600

Medication Costs with Co-pay Accumulator
Consumer
January

$0

Manufacturer Co-pay
Card
$3,090

February

$180

$2,910

March

$2,870

April - December

$450 ($50/month)

$0

Total

$3,500

$6,000

Total collected by
Insurance Plan

Plan deductible met

$0

$9,500

Manufacturer CAP max met

• Lack of Transparency
•

Patients Surprised

• HIV Community Sent letter to all State Insurance
Commissioners & Attorney Generals
•

Other patient groups follow

• Patient Groups need to Speak up
• Beneficiaries must be aware
•

Open enrollment begins November 1st

• Higher Out of Pocket Costs lead to lack of adherence

Ryan White
Funding

Is Ryan White Program funding distributed to areas most-in-need
and following the epidemic?
• Examine all Part A, B, C and D funding per state and case
counts
• Grants are based on formula, others based on need and who
applies
• Part B Supplemental and C & D presence greatly impacts a
state’s total funding

(Above/Below the Median)

(Above/Below the Median)

Total Part A-D Funding, Above/Below the Median, Multiplied by Total Cases

PR

•
•
•
•

•

OH, MA, the Marshall Islands, and American Samoa were not eligible
20 States applied
$218 million available; $177.8 million awarded
Highest awards:
• NY: $35m
• CA: $35m
• IN: $26.4m
Recipients: AL, AK, GA, ID, IA, ME, MN, MS, MO, MT, NE,NV, NJ, NC, PR,
RI, TX, US Virgin Islands, UT, WI

•

•

Proposes statutory changes to Parts A & B funding methodologies
– No specifics provided
– Allows for a data driven distribution to ensure funds are allocated
to populations experiencing high or increasing rates of infections
– Reduces burden on recipients and allows for better targeting of
resources
Increase HHS’s ability to effectively focus resources for HIV care,
treatment, and support needs in funded cities and states based on
need, geography, data quality, and performance.

• Reauthorization unlikely in near future, so The AIDS Institute is
focusing on improving distribution within current law
Supplementals and Parts C & D

• In the future, suggest distribution on case counts and other factors
such as:
• Death Rate
• Viral Suppression Rate
• Number of Clients using Ryan White Program
• Insurance Coverage
• Cost of care
• Poverty Rate

Key Federal
HIV/AIDS
Players

Alex Azar
Secretary of HHS

Seema Verma
CMS Administrator

Adm. Brett Giror
Assistant Sec. for Health

Robert Redfield
CDC Director

Katy Talento
Member, White House Policy Council

Joe Grogan
Associate Director, Health Program, OMB

• HHS Updating NHAS
•

Current one expires 2020

• Last updated in 2015
• First listening session held at USCA
• Additional opportunities for
stakeholder input to be announced

Midterm Election
– Changes in the Congress
• Leadership
• Committee Chairs and
Members
• New Members and Staff
President Trump

Carl Schmid
Deputy Executive Director
The AIDS Institute
202-462-3042
cschmid@theaidsinstitute.org

